Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd engages in the research, development, production, and sale of active pharmaceutical ingredients and formulations primarily in China. The company offers anti-anemia drugs such as compound ferrous sulfate folic acid tablets (Yiyuansheng) and ferrous sulfate; antipsychotic and antidepressant medications including risperidone tablets, escitalopram oxalate tablets, and rexianthin capsules; circulatory system drugs; tumor treatments; and raw materials like ferrous fumarate and revanillin, provided mainly in tablet and capsule forms. Founded in 1990 and headquartered in Panshi, Jilin Province, China, it operates with a focus on domestic markets while advancing a global strategy, employing around 320 people and listing on the Shenzhen Stock Exchange (301130.SZ). Recent developments include the approval of levofloxacin eye drops, enhancing its product portfolio in ophthalmic treatments, alongside ongoing shareholding reductions by major shareholders such as Hengqin Dingdian and affiliates in 2025, and modest net profit growth of 2.02% in the first half of 2025 to RMB 24.9446 million.